Vellanki P, et al. - In this prospective open-label multicentre study, researchers evaluated to ascertain the glycaemic efficiency and safety of linagliptin in comparison to a basal-bolus insulin regimen in hospitalized surgical cases with type 2 diabetes (T2D). They observed a higher mean daily blood glucose (BG) in the linagliptin group. They also noted that linagliptin produced minute hypoglycemic events, with similar supplemental insulin and fewer daily insulin injections as compared to the basal-bolus group. Overall daily linagliptin was considered a safe and productive choice to multi-dose insulin therapy.